Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer NCT04605731 BCLC Stage B He...
BCLC Stage C He...
Locally Advance...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Durvalumab
Tremelimumab
18 Years - City of Hope Medical Center View Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912 Metastatic Chol...
Metastatic Hepa...
Stage III Hepat...
Stage III Intra...
Stage IIIA Hepa...
Stage IIIA Intr...
Stage IIIB Hepa...
Stage IIIB Intr...
Stage IV Hepato...
Stage IV Intrah...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable Ch...
Unresectable He...
Unresectable In...
Carboplatin
Paclitaxel
Pevonedistat
18 Years - National Cancer Institute (NCI) View Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax NCT05092373 Advanced Breast...
Advanced Endome...
Advanced Fallop...
Advanced Hepato...
Advanced Malign...
Advanced Malign...
Advanced Malign...
Advanced Ovaria...
Advanced Primar...
Advanced Renal ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Malignant Abdom...
Malignant Solid...
Metastatic Brea...
Metastatic Endo...
Metastatic Fall...
Metastatic Hepa...
Metastatic Mali...
Metastatic Mali...
Metastatic Mali...
Metastatic Ovar...
Metastatic Prim...
Metastatic Rena...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Stage III Fallo...
Stage III Hepat...
Stage III Ovari...
Stage III Prima...
Stage III Renal...
Stage III Uteri...
Stage IIIA Fall...
Stage IIIA Hepa...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIA Uter...
Stage IIIA1 Fal...
Stage IIIA1 Ova...
Stage IIIA2 Fal...
Stage IIIA2 Ova...
Stage IIIB Fall...
Stage IIIB Hepa...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIB Uter...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Fallop...
Stage IV Hepato...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Renal ...
Stage IV Uterin...
Stage IVA Fallo...
Stage IVA Hepat...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVA Uteri...
Stage IVB Fallo...
Stage IVB Hepat...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Atezolizumab
Cabozantinib S-...
Nab-paclitaxel
Tumor Treating ...
18 Years - M.D. Anderson Cancer Center View Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904 Recurrent Hepat...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Laboratory Biom...
Lenvatinib
18 Years - Emory University View Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma NCT01176604 Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Yttrium Y 90 Gl...
- M.D. Anderson Cancer Center View An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer NCT04022746 Advanced Adult ...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Magnetic Resona...
Magnetic Resona...
18 Years - M.D. Anderson Cancer Center View Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904 Recurrent Hepat...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Laboratory Biom...
Lenvatinib
18 Years - Emory University View BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer NCT03695250 Metastatic Hepa...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
IDO1 Inhibitor ...
Nivolumab
18 Years - University of California, Davis View Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904 Recurrent Hepat...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Laboratory Biom...
Lenvatinib
18 Years - Emory University View Y-90 Versus SBRT for Inoperable HCC NCT05157451 Hepatocellular ...
Stage I Hepatoc...
Stage IA Hepato...
Stage IB Hepato...
Stage II Hepato...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IVA Hepat...
Quality of Life
Questionnaire A...
Stereotactic Bo...
Yttrium-90 Micr...
18 Years - OHSU Knight Cancer Institute View Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) NCT03896646 Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Computed Tomogr...
Hepatobiliary I...
Single Photon E...
Yttrium Y 90 Gl...
Yttrium-90 Micr...
18 Years - M.D. Anderson Cancer Center View Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma NCT01176604 Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Yttrium Y 90 Gl...
- M.D. Anderson Cancer Center View Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer NCT04380545 Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable Fi...
Fluorouracil
Nivolumab
Recombinant Int...
12 Years - M.D. Anderson Cancer Center View Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma NCT01176604 Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Yttrium Y 90 Gl...
- M.D. Anderson Cancer Center View A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab NCT05199285 BCLC Stage B He...
BCLC Stage C He...
Locally Advance...
Metastatic Hepa...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Ipilimumab
Nivolumab
18 Years - Academic and Community Cancer Research United View BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer NCT03695250 Metastatic Hepa...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
IDO1 Inhibitor ...
Nivolumab
18 Years - University of California, Davis View Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition NCT04430452 Advanced Hepato...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Durvalumab
Hypofractionate...
Tremelimumab
18 Years - University of California, San Francisco View